Navigation Links
Histogen’s Method of Generating Multipotent Stem Cells Receives US Patent
Date:9/3/2013

San Diego, CA (PRWEB) September 03, 2013

Histogen, Inc., a regenerative medicine company developing innovative therapies for conditions including hair loss and cancer, today announced that the United States Patent & Trademark Office has issued patent 8,524,494, entitled “Low Oxygen Tension and bFGF Generates a Multipotent Stem Cell from a Fibroblast In Vitro” to the Company.

The issued patent covers Histogen’s method of triggering the de-differentiation of fibroblast cells into multipotent stem cells through low oxygen and special culture conditions. The resulting multipotent cells naturally secrete a variety of soluble and insoluble molecules that are the basis for Histogen’s products.

“Histogen’s process is uniquely capable of harnessing all of the benefits and excitement of stem cell therapies without any of the ethical, safety or sourcing concerns,” said Dr. Gail K. Naughton, Histogen CEO and Chairman of the Board. “Issuance of this patent adds great strength to our technology, and value to our partners and products.”

Current stem cell-derived therapies utilize embryonic stem cells or genetically-manipulated induced pluripotent stem cells, both of which have an inherent ethical and scientific risk, and raise a number of regulatory issues. Still, enthusiasm continues to build around stem cells, both for their potential to address serious medical conditions as well as their aesthetic benefits for beauty and rejuvenation.

Through Histogen’s technology process, the Company is uniquely able to begin with newborn fibroblasts cells, a safe, well-established and non-controversial cell source, and convert the cells into multipotent stem cells without genetic manipulation. The cells express key stem cell markers including Oct4, Sox2 and Nanog, and secrete a distinctive composition of growth factors and other proteins known to stimulate stem cells in the body, regenerate tissues, and promote scarless healing.

It is the soluble and insoluble compositions of multipotent proteins and growth factors which make up Histogen’s products, with numerous applications. Histogen’s lead product, Hair Stimulating Complex (HSC) has shown success in two Company-sponsored clinical trials as an injectable treatment for alopecia. In addition, the human multipotent cell conditioned media produced through Histogen’s process can be found in the ReGenica line of skincare products, currently being distributed by Suneva Medical in partnership with Obagi Medical Products. Further indications of the materials currently being developed include oncology and orthopedics.

About Histogen
Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen’s technology focuses on stimulating a patient’s own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit http://www.histogen.com.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11083274.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. New method for producing precursor of neurons, bone and other important tissues from stem cells
2. UCLA team develops highly efficient method for creating flexible, transparent electrodes
3. New method for enhancing thermal conductivity could cool computer chips, lasers and other devices
4. New laboratory method uses mass spectrometry to rapidly detect staph infections
5. Novel method to make nanomaterials discovered
6. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
7. New method yields insulin-producing pancreatic cell clusters
8. X-BODY BioSciences to Present Novel Methods of Selecting for Antibodies Against Targets on Live Cells at CHIs Protein Engineering Summit
9. Fabrication method can affect the use of block copolymer thin films
10. New UCLA method quickly IDs nanomaterials that can cause oxidative damage to cells
11. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... Supplyframe, the Industry Network for electronics ... Lab . Located in Pasadena, Calif., the Design Lab’s mission is to bring ... designed, built and brought to market. , The Design Lab is Supplyframe’s physical ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a ... designed, tuned and optimized exclusively for Okuma CNC machining centers at The International ... a collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):